瑞舒伐他汀对急性冠脉综合征患者颈动脉斑块的作用

目的：探讨瑞舒伐他汀对急性冠脉综合征患者颈动脉斑块的影响及机制。方法：对随机70例急性冠脉综合征患者常规治疗外，加用瑞舒伐他汀10mg，每晚1次。治疗6个月后测总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇（HDL—C）及超敏C反应蛋白（hs-CRP）的水平，采用彩色多普勒测定治疗前后颈动脉内膜的厚度及颈动脉斑块的变化。结果：瑞舒伐他汀治疗后6个月，患者TC、LDL-C、hs—CRP显著低于治疗前水平（P〈0．01）。双侧颈动脉内膜厚度及颈动脉斑块缩小程度，与治疗前比较有显著差异（P〈0．01）。结论：瑞舒伐他汀通过降低血脂、降低hs—CRP水平，稳定急性冠脉综合征患者颈动脉斑块。

Effect of Rosurastain on Carotid Plaques in Patients With Acute Coronary Syndrome

Objective： To explore the effect of rosurastain on carotid plaques in patients with acute coronary syn drome （ACS）. Methods： Seventy cases of ACS received rosurastain 10mg every night on the basis of routine treatment. Serum levels of TC, LDL-C, HDL-C and hs-CRP were measured 6 months after treatment. The intima-media thickness （IMT） and atherosclerotic plaques were measured by means of ultrasound before and 6 months after therapy. Results： Serum levels of TC, LDL-C, hs-CRP dereased significantly （P〈0. 01）and IMT, atherosclerotic plaques decreased 6 months after treatment （P〈0. 01）. Conclusions： Rosurastain can stabilize carotid plaques in ACS by decreasing the serum level of TC, LDL-C and hs-CRP.